Unlocking the full potential of biosimilars

Ageing populations, the rise of chronic diseases, and healthcare systems stretched to breaking point by COVID-19, all raise questions over the long-term sustainability of healthcare.  Biosimilars, follow on medicine of an existing biologic when the patent has expired, are effective but often underused options to help treat many diseases while reducing spending on medicines and freeing up resources to invest in other areas.With healthcare systems working hard to get back on track, will 2021 be the year that biosimilars are able to deliver more fully on their promise of more affordable, accessible and sustainable treatments for patients?  Data science company IQVIA has been watching developments in biosimilars since the first product was licensed in Europe in 15 year ago and believes that biosimilars could be a valuable tool in creating more sustainable healthcare systems. Speaking at a recent virtual event, a collaboration between global biosimilars leader, Sandoz, and Reuters Events Pharma, Murray Aitken, the IQVIA Institute ’s Executive Director, said: “We are at a significant point today where we see biosimilars playing a meaningful role in health systems in many countries around the world.”How biosimilars can deliver better outcomes for patients and healthcare systems  The IQVIA Institute estimates that over the next five years biosimilars could globally contribute a cumulative $285 billion of savings to payers. To put this in context, over the same period, around...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news